PHILADELPHIA, Dec. 12, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony ® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, is pleased to announce that its clinical study was selected for poster presentation at the Society of Critical Care Medicine's 42 nd Critical Care Congress which will be held January 19-23, 2013 in San Juan, Puerto Rico. The study will be presented by the principal investigator, Stanley A. Nasraway, M.D., FCCM, during Display and Professor Walk Rounds on Sunday, January 20, 2013 from 12:45-1:45 PM AST.
The poster, entitled "Accuracy of a Novel Non-Invasive Transdermal Continuous Glucose Monitor in Critically Ill Patients," will highlight the positive results from the clinical study of Echo's Symphony tCGM System in critically ill patients at Tufts Medical Center in Boston, MA.
"We are excited to present these positive clinical study results as we continue to build awareness of our Symphony tCGM System and the benefits it can provide to critically ill patients. These clinical results represent the substantial progress we have made in the Symphony development program," stated Patrick T. Mooney, M.D., Echo's Chairman and CEO. "We look forward to beginning our European and U.S. clinical regulatory trials and bringing Symphony to commercialization to support clinicians in hospital-based glucose management."About Echo Therapeutics Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system. Our target is patients who could benefit from glucose monitoring in the hospital setting, including critical care. Significant opportunity also exists for patients with diabetes to use Symphony in the outpatient setting. Echo is also developing its needle-free skin preparation component of Symphony, the Prelude ® SkinPrep System, as a platform technology to enhance drug delivery of topical pharmaceuticals. Cautionary Statement Regarding Forward Looking Statements The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the safety and efficacy of Echo's Symphony tCGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2011, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements. For More Information:Christine H. Olimpio Director, Investor Relations and Corporate Communications (215) 717-4104 email@example.com Connect With Us:- Visit our website at www.echotx.com- Follow us on Twitter at www.twitter.com/echotx- Join us on Facebook at www.facebook.com/echotx SOURCE Echo Therapeutics, Inc.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV